

Duty of Disclosure to the Patent Office

Patent Application Title: IMIDAZO[1,2-A]PYRAZINE DERIVATIVES
Supervising Attorney/Agent: PEGUET, Wilfried
Syngenta File No.: 82933-WO-REG-ORG-P-1
EP / 23167802.0 / 13 Apr 2023
Patent Application Serial No.:


We are currently assembling the appropriate disclosure documents to submit to the U.S. Patent and Trademark Office for the above-referenced patent application. Each individual associated with the filing and prosecution of a patent application, including the inventors, has an absolute, affirmative, and on-going duty to disclose to the Patent Office any information known to them that is “material” to the examination of the patent application. Information is considered to be “material” when that information, by itself or when combined with other information, either (i) establishes on its face the unpatentability of this invention, or (ii) is inconsistent with arguments of patentability made to the Patent Office. FAILURE TO DISCLOSE ALL MATERIAL INFORMATION MAY SERVE AS THE BASIS FOR LOSS OF PATENT RIGHTS.

Please provide us with information and/or references (prior publications, knowledge, patents, foreign patents, offers for sale, public uses, etc.) that you consider relevant to the examination of this patent application. Once we receive any additional information from you, we will file a complete disclosure to the Patent Office.

YOU MUST RETURN A SIGNED COPY OF THIS MEMO TO GROESSINGER, Jan WITHIN **TWO WEEKS** OF RECEIPT, REGARDLESS OF WHETHER YOU HAVE ADDITIONAL INFORMATION TO REPORT.


As the duty to disclose is on-going, please contact us immediately, if you subsequently become aware of additional information and/or references that you consider relevant to the examination of this patent application.

Please do not hesitate to contact the Supervising Attorney/Agent should you have questions.



I have no additional information to report.

Additional information is attached.



POULIOT, Martin
25 April 2024

Duty of Disclosure to the Patent Office

Patent Application Title: IMIDAZO[1,2-A]PYRAZINE DERIVATIVES
Supervising Attorney/Agent: PEGUET, Wilfried
Syngenta File No.: 82933-WO-REG-ORG-P-1
Patent Application Serial No.: EP / 23167802.0 / 13 Apr 2023

We are currently assembling the appropriate disclosure documents to submit to the U.S. Patent and Trademark Office for the above-referenced patent application. Each individual associated with the filing and prosecution of a patent application, including the inventors, has an absolute, affirmative, and on-going duty to disclose to the Patent Office any information known to them that is "material" to the examination of the patent application. Information is considered to be "material" when that information, by itself or when combined with other information, either (i) establishes on its face the unpatentability of this invention, or (ii) is inconsistent with arguments of patentability made to the Patent Office. **FAILURE TO DISCLOSE ALL MATERIAL INFORMATION MAY SERVE AS THE BASIS FOR LOSS OF PATENT RIGHTS.**

Please provide us with information and/or references (prior publications, knowledge, patents, foreign patents, offers for sale, public uses, etc.) that you consider relevant to the examination of this patent application. Once we receive any additional information from you, we will file a complete disclosure to the Patent Office.

YOU MUST RETURN A SIGNED COPY OF THIS MEMO TO GROESSINGER, Jan WITHIN TWO WEEKS OF RECEIPT, REGARDLESS OF WHETHER YOU HAVE ADDITIONAL INFORMATION TO REPORT.

As the duty to disclose is on-going, please contact us immediately, if you subsequently become aware of additional information and/or references that you consider relevant to the examination of this patent application.

Please do not hesitate to contact the Supervising Attorney/Agent should you have questions.

✓ I have no additional information to report.

_____ Additional information is attached.


JEANMART, Stephane André Marie
25 April 2024

Duty of Disclosure to the Patent Office

Patent Application Title: IMIDAZO[1,2-A]PYRAZINE DERIVATIVES
Supervising Attorney/Agent: PEGUET, Wilfried
Syngenta File No.: 82933-WO-REG-ORG-P-1
Patent Application Serial No.: EP / 23167802.0 / 13 Apr 2023

We are currently assembling the appropriate disclosure documents to submit to the U.S. Patent and Trademark Office for the above-referenced patent application. Each individual associated with the filing and prosecution of a patent application, including the inventors, has an absolute, affirmative, and on-going duty to disclose to the Patent Office any information known to them that is "material" to the examination of the patent application. Information is considered to be "material" when that information, by itself or when combined with other information, either (i) establishes on its face the unpatentability of this invention, or (ii) is inconsistent with arguments of patentability made to the Patent Office. **FAILURE TO DISCLOSE ALL MATERIAL INFORMATION MAY SERVE AS THE BASIS FOR LOSS OF PATENT RIGHTS.**

Please provide us with information and/or references (prior publications, knowledge, patents, foreign patents, offers for sale, public uses, etc.) that you consider relevant to the examination of this patent application. Once we receive any additional information from you, we will file a complete disclosure to the Patent Office.

YOU MUST RETURN A SIGNED COPY OF THIS MEMO TO GROESSINGER, Jan WITHIN TWO WEEKS OF RECEIPT, REGARDLESS OF WHETHER YOU HAVE ADDITIONAL INFORMATION TO REPORT.

As the duty to disclose is on-going, please contact us immediately, if you subsequently become aware of additional information and/or references that you consider relevant to the examination of this patent application.

Please do not hesitate to contact the Supervising Attorney/Agent should you have questions.

X I have no additional information to report.

 Additional information is attached.

N. Germain
GERMAIN, Nicolas
25 April 2024

Duty of Disclosure to the Patent Office

Patent Application Title: IMIDAZO[1,2-A]PYRAZINE DERIVATIVES
Supervising Attorney/Agent: PEGUET, Wilfried
Syngenta File No.: 82933-WO-REG-ORG-P-1
Patent Application Serial No.: EP / 23167802.0 / 13 Apr 2023

We are currently assembling the appropriate disclosure documents to submit to the U.S. Patent and Trademark Office for the above-referenced patent application. Each individual associated with the filing and prosecution of a patent application, including the inventors, has an absolute, affirmative, and on-going duty to disclose to the Patent Office any information known to them that is "material" to the examination of the patent application. Information is considered to be "material" when that information, by itself or when combined with other information, either (i) establishes on its face the unpatentability of this invention, or (ii) is inconsistent with arguments of patentability made to the Patent Office. **FAILURE TO DISCLOSE ALL MATERIAL INFORMATION MAY SERVE AS THE BASIS FOR LOSS OF PATENT RIGHTS.**

Please provide us with information and/or references (prior publications, knowledge, patents, foreign patents, offers for sale, public uses, etc.) that you consider relevant to the examination of this patent application. Once we receive any additional information from you, we will file a complete disclosure to the Patent Office.

YOU MUST RETURN A SIGNED COPY OF THIS MEMO TO GROESSINGER, Jan WITHIN TWO WEEKS OF RECEIPT, REGARDLESS OF WHETHER YOU HAVE ADDITIONAL INFORMATION TO REPORT.

As the duty to disclose is on-going, please contact us immediately, if you subsequently become aware of additional information and/or references that you consider relevant to the examination of this patent application.

Please do not hesitate to contact the Supervising Attorney/Agent should you have questions.

X I have no additional information to report.

 Additional information is attached.


LE CHAPELAIN, Camille
25 April 2024

INDONESIA

SURAT PERNYATAAN KEPEMILIKAN INVENSI (OLEH INVENTOR)
STATEMENT OF INVENTORSHIP (BY INVENTOR)

Yang bertanda tangan di bawah ini:
The undersigned:

Nama Inventor Kewarganegaraan
Inventor(s) *Citizenship*

POULIOT, Martin; citizen of Canada
JEANMART, Stephane André Marie; citizen of Belgium
GERMAIN, Nicolas; citizen of France
LE CHAPELAIN, Camille; citizen of France


Dengan ini saya/kami menyatakan bahwa, InvenSI yang berjudul:
I / We hereby declare that the invention entitled:

IMIDAZO[1,2-A]PYRAZINE DERIVATIVES


adalah milik saya/kami dan tidak meniru InvenSI orang lain.
is my/our own invention, it is neither a duplication nor does it constitute an imitation of any invention owned by another person.


Demikian pernyataan ini saya/kami buat dengan sebenarnya, untuk dipergunakan sebagaimana mestinya.
This statement is made genuinely and is to be used accordingly.

pernyataan ini dilaksanakan pada:
this statement was effected on: **25 April 2024**


POULIOT, Martin


JEANMART, Stephane André Marie


GERMAIN, Nicolas


LE CHAPELAIN, Camille

**PEMINDAHAN HAK
ASSIGNMENT OF CONVENTION RIGHTS
FOR PATENT APPLICATION IN INDONESIA**

The undersigned:

(1) Assignor(s):

POULIOT, Martin
Syngenta Crop Protection AG
Schaffhauserstrasse
4332 Stein
Switzerland
Citizenship: Canada
Country of Residence: France

JEANMART, Stephane André Marie
Syngenta Crop Protection AG
Schaffhauserstrasse
4332 Stein
Switzerland
Citizenship: Belgium
Country of Residence: France

GERMAIN, Nicolas
Syngenta Crop Protection AG
Schaffhauserstrasse
4332 Stein
Switzerland
Citizenship: France
Country of Residence: France

LE CHAPELAIN, Camille
Syngenta Crop Protection AG
Schaffhauserstrasse
4332 Stein
Switzerland
Citizenship: France
Country of Residence: Switzerland

(2) Assignee(s):

SYNGENTA CROP PROTECTION AG, Rosentalstrasse 67, 4058 Basel, Switzerland

declare

that the undersigned sub 1 has (have) assigned to the undersigned sub 2, the latter in turn accepting from the former, the right to apply for a patent in Indonesia for the invention, the title of which reads:


IMIDAZO[1,2-A]PYRAZINE DERIVATIVES


and for which the undersigned (sub 2) applied for letters patent on **11 April 2024** as
PCT/EP2024/059875

claiming the convention rights accruing from the application
EP / 23167802.0 / 13 Apr 2023


that this assignment was effected on **25 April 2024**

(1) Assignor(s):


POULIOT, Martin


JEANMART, Stephane André Marie



GERMAIN, Nicolas


LE CHAPELAIN, Camille

(2) Assignee(s):

SYNGENTA CROP PROTECTION AG

Signature:


Printed Name: 
GROESSINGER, Jan

Title: **Authorised signatory**

Date: **15. Mai 2024**

SYNGENTA CROP PROTECTION AG

Signature:

Printed Name: 
Jan Groessinger

Title: **Authorised signatory**

Date: **15. Mai 2024**

**ASSIGNMENT OF INVENTION
CESIÓN DE INVENCIÓN**

Be it known that
Sepan todos por la presente que

Inventor's name and address
Nombre y domicilio de inventor

POULIOT, Martin
Syngenta Crop Protection AG
Schaffhauserstrasse
4332 Stein
Switzerland
Citizenship: Canada
Country of Residence: France

JEANMART, Stephane André Marie
Syngenta Crop Protection AG
Schaffhauserstrasse
4332 Stein
Switzerland
Citizenship: Belgium
Country of Residence: France

GERMAIN, Nicolas
Syngenta Crop Protection AG
Schaffhauserstrasse
4332 Stein
Switzerland
Citizenship: France
Country of Residence: France

LE CHAPELAIN, Camille
Syngenta Crop Protection AG
Schaffhauserstrasse
4332 Stein
Switzerland
Citizenship: France
Country of Residence: Switzerland

Inventor(s) of:
Inventor(es) de:

Leave blank
Dejar en blanco

Declare(s) that he/they assign(s), sell(s) and transfer(s) in full ownership
and dominion to
Declara(n) que cede(n), vende(n) y traspara(n) en toda propiedad y
dominio a

Assignee's name
Nombre del Cesionario

**SYNGENTA CROP PROTECTION AG, Rosentalstrasse 67, 4058 Basel,
Switzerland**

For the amount of \$50.00 (fifty Pesos) Mexican Currency and other valuable considerations of non-patrimonial nature, the referred invention as well as in its case, the corresponding priority right and other related rights without any exception; the assignee should consequently, be considered from now on, its owner, to patent it, to exploit it and to dispose of it at his best convenience, without any further claim on the part of the assignor(s) in any form or time.

Por la cantidad de \$50.00 (cincuenta pesos) moneda mexicana y otras valiosas consideraciones de índole no patrimonial la invención referida así como en su caso el derecho a la prioridad y demás derechos que le corresponden sin excepción alguna, pudiendo por consiguiente, desde hoy considerarse como dueña de ella, patentarla, explotarla y disponer de la misma como mejor conviniere a sus intereses, sin que pueda haber reclamo ulterior de su parte, en cualquier forma o tiempo.

Place
Lugar


Place of execution: Stein
a


Date
Fecha


Date of execution: **25 April 2024**
Firmado lo anterior en:


ASSIGNOR(S)
CEDENTE(S)

Inventor's signature
Firma de inventor


POULIOT, Martin


JEANMART, Stephane André Marie


GERMAIN, Nicolas






LE CHAPELAIN, Camille


NOTE: NOTARIZATION OR LEGALIZATION NOT REQUIRED.
NOTA: NO SE REQUIERE NOTARIZACIÓN O LEGALIZACIÓN.



ASSIGNMENT – PRIORITY / WORLDWIDE / PATENT COOPERATION TREATY (PCT) COUNTRIES	CESIÓN – PRIORIDAD / EN TODO EL MUNDO / PAÍSES DEL TRATADO DE COOPERACIÓN EN MATERIA DE PATENTES (PCT)
For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, POULIOT, Martin Syngenta Crop Protection AG Schaffhauserstrasse 4332 Stein Switzerland Citizenship: Canada Country of Residence: France JEANMART, Stephane André Marie Syngenta Crop Protection AG Schaffhauserstrasse 4332 Stein Switzerland Citizenship: Belgium Country of Residence: France GERMAIN, Nicolas Syngenta Crop Protection AG Schaffhauserstrasse 4332 Stein Switzerland Citizenship: France Country of Residence: France	Por una buena y valiosa contraprestación, cuyo recibo y cantidad suficiente se confirma por la presente, POULIOT, Martin Syngenta Crop Protection AG Schaffhauserstrasse 4332 Stein Switzerland Citizenship: Canada Country of Residence: France JEANMART, Stephane André Marie Syngenta Crop Protection AG Schaffhauserstrasse 4332 Stein Switzerland Citizenship: Belgium Country of Residence: France GERMAIN, Nicolas Syngenta Crop Protection AG Schaffhauserstrasse 4332 Stein Switzerland Citizenship: France Country of Residence: France
LE CHAPELAIN, Camille Syngenta Crop Protection AG Schaffhauserstrasse 4332 Stein Switzerland Citizenship: France Country of Residence: Switzerland has sold and assigned, and by this document hereby sells and assigns, unto SYNGENTA CROP PROTECTION AG, Rosentalstrasse 67, 4058 Basel, Switzerland its successors and assigns, the entire right, title and interest, so far as concerns the United States and the Territories and Possessions thereof and all foreign countries and including members of the Patent Cooperation Treaty (PCT) in and to (1) all inventions and discoveries described in Syngenta Patent Family 82933	LE CHAPELAIN, Camille Syngenta Crop Protection AG Schaffhauserstrasse 4332 Stein Switzerland Citizenship: France Country of Residence: Switzerland ha(n) vendido y cedido, y por medio de lo presente, vende(n) y cede(n) por la presente a SYNGENTA CROP PROTECTION AG, Rosentalstrasse 67, 4058 Basel, Switzerland sus sucesoras y cesionarias, el derecho, título e interés completos, por lo que respecta a los Estados Unidos y sus territorios y posesiones y a todos los países extranjeros e incluso los miembros del Tratado de Cooperación en Materia de Patentes (PCT) en y sobre

including those described in IMIDAZO[1,2-A]PYRAZINE DERIVATIVES, and including, but not limited to, the following filings: Country / Application Number / Filing Date EP / 23167802.0 / 13 Apr 2023 (2) said invention and provisional and/or priority application and in and to any and all subsequent patent applications which claim the benefit of priority from said provisional and/or priority application including regular utility, continuations, and continuations-in-part, or divisions thereof; (3) said invention in and to any said patent application for United States Letters Patent(s) and foreign countries relating to all patent application(s) filed in respect of the invention, including all divisional, renewal, substitute, reissues, continuation, non-provisional(s), International Patent Application(s); (4) all national phase patent applications of said International Patent Application(s);	(1) todas las invenciones y descubrimientos descritos en la familia de patentes de Syngenta 82933 incluso aquellos descritos en IMIDAZO[1,2-A]PYRAZINE DERIVATIVES e incluidas, pero no limitadas, las siguientes solicitudes: País / Número de Solicitud / Fecha de Presentación EP / 23167802.0 / 13 Apr 2023 (2) dicha invención y solicitud provisional y/o de prioridad en y sobre todas y cada una de las solicitudes de patente posteriores que reivindiquen el beneficio de prioridad de dicha solicitud provisional y/o de prioridad, incluso la utilidad regular, continuaciones y continuaciones en parte, o divisiones de estas; (3) dicha invención en y sobre cualquier solicitud de patente mencionada para la(s) patente(s) de los Estados Unidos y países extranjeros relacionadas con todas las solicitudes de patente presentadas respecto a la invención, incluso todas las solicitudes de patente internacional, no provisionales, continuaciones, nuevas emisiones, sustituciones, renovaciones y divisiones;
(5) all continuations (including continuation-in-parts, Convention applications, divisions of all of said patent application(s) (including further continuations and divisions such as, but not limited to, continuations of continuations and continuations of divisions), ((2)-(5) hereinafter referred to collectively as "patent applications"); (6) all patents that are granted on any of said patent applications; (7) all registrations and confirmations of and importation certificates based on one or more of said patents; (8) all substitutes, reissues, renewals and extensions of said patents, reexamination certificates issued for said patents and supplementary protection certificates based in whole or in part upon said inventions or upon said applications, and any and all Letters Patent and reissues, reexaminations, and extensions of Letters Patent granted for said inventions or upon said applications and on said patents;	(4) todas las solicitudes de fase nacional de dicha(s) solicitud(es) de patente internacional; (5) todas las continuaciones (incluso continuación en partes), solicitudes de convención y divisiones de todas las solicitudes de patente mencionadas (incluso demás continuaciones y divisiones, tales como, pero no limitadas a, continuaciones de continuaciones y continuaciones de divisiones), ((2)-(5) más adelante llamadas colectivamente "solicitudes de patente"); (6) todas las patentes que se conceden sobre cualquiera de dichas solicitudes de patente; (7) todos los registros y confirmaciones de, o certificados de importación en base de una o más de dichas patentes; (8) todas las sustituciones, nuevas emisiones, renovaciones y extensiones de dichas patentes, certificados de re-examinación emitidos para dichas patentes y certificados de protección complementaria basándose por completo o en parte en dichas invenciones o en dichas solicitudes, y todas y cada una de las patentes y

(9) every priority right and right to claim priority that is or may be predicated upon or arise from said inventions, said patent applications and said patents; said Assignee being hereby authorized to file patent applications in any or all countries to any or all said inventions in the name of the undersigned or in the name of said Assignee or otherwise as said Assignee may deem advisable, under any international patent treaty (e.g. Patent Cooperation Treaty, Paris Convention, etc.) or otherwise; all Patent Offices (U.S. and foreign) being hereby authorized to issue or transfer all said patents to said Assignee in accordance herewith;	nuevas emisiones, re-examinaciones y extensiones de la patente concedidas a dichos inventores o en dichas solicitudes y en dichas patentes; (9) cada derecho prioritario basado o que se pueda basar en o que surge de dichas invenciones, dichas solicitudes de patentes y dichas patentes; autorizando a dicha Cesionaria para que presente solicitudes de patente en cualquier o todos los países o cualquier o todas dichas invenciones en nombre del abajo firmante o en nombre de dicha Cesionaria o de otra forma según pueda considerar aconsejable dicha Cesionaria, bajo cualquier tratado de patente internacional (p. ej., el Tratado de Cooperación en Materia de Patentes, la Convención de París, etc.) o de otra forma; autorizando por la presente a todas las Oficinas de Patentes (de los Estados Unidos y extranjeras) para que emitan o transfieran todas dichas patentes a dicha Cesionaria de acuerdo con la presente;
this assignment being under covenant, not only that full power to make the same is had by the undersigned, but also that such assigned right is not encumbered by any grant, license, or other right theretofore given, and that the undersigned will to all acts reasonably serving to ensure that the said inventions, patent applications and patents shall be held and enjoyed by said Assignee as fully and entirely as the same could have been held and enjoyed by the undersigned if this assignment had not been made, and particularly to execute and deliver to said Assignee all lawful documents including petitions, specifications, oaths, assignments, invention disclaimers, declarations, and lawful affidavits in form and substance which may be requested by said Assignee, to furnish said Assignee with all facts relating to said inventions or the history thereof and any and all documents, photographs, models, samples or other physical exhibits which may embody said inventions, and to testify in any proceedings relating to said inventions, patent applications, and/or patents. The undersigned hereby grant(s) an authorized representative of Assignee the power to insert in this Assignment any further identification that may be necessary or desirable to comply with the rules of any Patent and Trademark Office for recordation of this Assignment.	estando esta cesión bajo el acuerdo, no solo de que el abajo firmante posea el poder completo para ejecutarla, sino que también dicho derecho cedido no se vea afectado por ninguna concesión, licencia ni otro derecho concedido hasta entonces, y que el abajo firmante actuará razonablemente, a todos los efectos, para garantizar que dichas invenciones, solicitudes de patente y patentes sean conservadas y disfrutadas por dicha Cesionaria tan completa y enteramente como si estas hubieran sido conservadas y disfrutadas por el abajo firmante si esta cesión no se hubiera llevado a cabo, y particularmente para ejecutar y proporcionar a dicha Cesionaria todos los documentos legales, incluso peticiones, especificaciones, juramentos, cesiones, renunciaciones de invención, declaraciones y actas notariales legales en forma y sustancia que puedan ser requeridas por dicha Cesionaria, para proporcionar a dicha Cesionaria todos los hechos relacionados con dichas invenciones o su historial y todos y cada uno de los documentos, fotografías, modelos, muestras u otras exhibiciones físicas que puedan representar dichas invenciones, y para testificar en cualesquiera procedimientos relacionados con dichas invenciones, solicitudes de patente y/o patentes. Por la presente, el (los) abajo firmante(s) concede(n) a un representante autorizado de la Cesionaria la facultad para que inserte en la presente Cesión cualquier identificación adicional que sea necesaria o deseable para cumplir las

Inventor's name and signature / Inventors' names and signatures & Date of signing Witness' name and signature / Witnesses' names and signatures & Date of signing  POULIOT, Martin 25 April 2024  Witness signature Ottmar Franz Hüter Witness printed name 25 April 2024  JEANMART, Stephane André Marie 25 April 2024	normas de cualquier Oficina de Patentes para la inscripción de la presente Cesión. Nombre y firma del Inventor / Nombres y firmas de los Inventores y Fecha Nombre y firma del Testigo / Nombres y firmas de los Testigos y Fecha
 Witness signature Friederike Brüssow Witness printed name 25 April 2024  GERMAIN, Nicolas 25 April 2024  Witness signature Michel Mühlebach Witness printed name 25 April 2024	

 LE CHAPELAIN, Camille 25 April 2024	
 Witness signature	
 Witness printed name 25 April 2024	

Applicant(s) / Signature	Solicitante(s) / Firma
SYNGENTA CROP PROTECTION AG Signature:  Printed Name: GROESSINGER, Jan Title: Authorised signatory Date: 15. Mai 2024	SYNGENTA CROP PROTECTION AG Por: Nombre: Cargo: Signatario autorizado Fecha:
SYNGENTA CROP PROTECTION AG Signature:  Printed Name: Dawn Rozal Title: Authorised signatory Date: 15. Mai 2024	SYNGENTA CROP PROTECTION AG Por: Nombre: Cargo: Signatario autorizado Fecha: